Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 22

Trial Status

Completed2
Terminated1

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT00450814Phase 1/2Completed
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
PrincipalinvestigatorStart date: 2006-11-30
NCT00030381Phase 1Terminated
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Primary Systemic Amyloidosis
Principalinvestigator
NCT00047203Phase 2Completed
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Shaji Kumar, M.D.

Mayo Clinic

Related
7 trials

Shared therapeutic areas:

Recurrent Plasma Cell MyelomaRefractory Multiple MyelomaImmunoglobulin Light-chain Amyloidosis+3 more

Worked with same sponsors:

Mayo ClinicNational Cancer Institute (NCI)
Similarity Score26%

Shaji Kumar

Mayo Clinic

Related
10 trials

Shared therapeutic areas:

Refractory Multiple MyelomaStage III Multiple MyelomaRecurrent Plasma Cell Myeloma+3 more

Worked with same sponsors:

Mayo ClinicNational Cancer Institute (NCI)
Similarity Score26%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score21%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score21%

Leona Holmberg

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score21%

Pamela Becker

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
5 trials

Shared therapeutic areas:

Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score17%

Mohamad A. Hussein, MD

The Cleveland Clinic

Related
8 trials

Shared therapeutic areas:

Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Refractory Multiple MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

Charles Erlichman

Mayo Clinic

Related
6 trials

Shared therapeutic areas:

Refractory Multiple MyelomaStage III Multiple Myeloma

Worked with same sponsors:

Mayo ClinicNational Cancer Institute (NCI)
Similarity Score9%

Sikander Ailawadhi, M.D.

Mayo Clinic

Related
6 trials

Shared therapeutic areas:

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Worked with same sponsors:

Mayo Clinic
Similarity Score9%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT00450814Phase 1/2PrincipalInvestigator

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Completed
NCT00030381Phase 1PrincipalInvestigator

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis
Terminated
NCT00047203Phase 2PrincipalInvestigator

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Completed

All 3 trials loaded